There is little in terms of novel therapy being explored for future treatment of Hansen's disease, and the same is true for many diseases caused by Mycobacterium species. The diarylquinolone, R207910, is a promising new drug with bactericidal activity comparable to that of moxifloxacin and rifapentine. Its novel mechanism is believed to be inhibition of ATP synthase. In a murine model, R207910 retained bactericidal capabilities even when dosed once/month. Although it must be studied in humans, this drug remains an exciting option for the future.
Pharmacotherapy. 2012;32(1):27-37. © 2012 Pharmacotherapy Publications